The incremental cost-effectiveness ratio (ICER) often comes up when talking about drug comparisons, but what is it and how does it relate to medicines?
What is the incremental cost-effectiveness ratio (ICER)?
Generics/General
|
Posted 03/12/2010
0
Post your comment
A health economic evaluation involves a comparative analysis where a therapeutic intervention is compared to another health technology.
The results of this analysis are expressed by means of an incremental cost-effectiveness ratio (ICER), which is defined as the ratio of the change in costs of a therapeutic intervention (compared to the alternative, such as doing nothing or using the best available alternative treatment) to the change in effects of the intervention.
Incremental cost-effectiveness ratio (ICER) = (C1 – C0) / (E1 – E0)
Where C1 is the cost of the medicine; C0 is the cost of the comparator technology; E1 and E0 are the consequences of the medicine and the comparator, respectively.
The change in effects is usually measured in terms of the number of life-years gained or quality-adjusted life years gained by the intervention.
Related article
Market access for biopharmaceuticals and biosimilars: a case study
Source: Steven Simoens. Personal Communication. 30 September 2010.
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
EMA launches European shortages monitoring platform to tackle persistent medicine shortages
Generics/General Posted 03/12/2024
FDA releases one-year progress report for the Generic Drug Cluster
Generics/General Posted 28/10/2022
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment